Who
Hunter C. Smith
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Rhythm Pharmaceuticals; Director, Spyre Therapeutics; Director, Genesee & Wyoming.
In numbers
- Trades disclosed
- 211
- Buys
- 0
- Sells
- 29
- Bought
- $0
- Sold
- $28.3M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 31 Mar 2015
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.5M57,187 at $25.79 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.4M23,072 at $104.59 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M11,514 at $105.37 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,187 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.0M28,188 at $106.20 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,187 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.5M57,187 at $25.79 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.4M23,072 at $104.59 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M11,514 at $105.37 | filing |
| 31 Aug 2026filed 1 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.0M28,188 at $106.20 | filing |
| 18 May 2026filed 20 May 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $54K3,000 at $17.87 | filing |
| 18 May 2026filed 20 May 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $54K3,000 at $17.87 | filing |
| 2 Mar 2026filed 2 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $41K6,099 at $6.80 | filing |
| 2 Mar 2026filed 2 Mar 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,099 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,099 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $41K6,099 at $6.80 | filing |
| 19 Feb 2026filed 19 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $131K1,308 at $100.27 | filing |
| 19 Feb 2026filed 19 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $171K1,692 at $100.92 | filing |
News
Contrasting Rhythm Pharmaceuticals (NASDAQ:RYTM) & ADMA Biologics (NASDAQ:ADMA)RYTM · dailypolitical.com · 22 Oct 2026Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Hunter C. Smith; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.